Cellectis (CLLS) Non-cash Items (2015 - 2026)
Cellectis' (CLLS) quarterly Non-cash Items came in at -$26.5 million in Q1 2026, down 2955.99% year-on-year from $927000.0 in Q1 2025, and up 70.98% quarter-over-quarter from -$91.2 million in Q3 2025.
Cellectis (CLLS) Non-cash Items (2015 - 2026) Analysis & Trends
Cellectis' Non-cash Items history runs 12 years deep, the most recent figure standing at -$26.5 million for Q1 2026.
- On a quarterly basis, Non-cash Items fell 2955.99% year-over-year to -$26.5 million in Q1 2026; TTM through Mar 2026 was -$120.1 million, a 600.21% decrease from a year earlier, with the FY2016 full-year figure at -$85.4 billion, down 139.41% from the prior year.
- Non-cash Items improved to -$26.5 million in Q1 2026 per CLLS's latest filing, from -$91.2 million in the prior quarter.
- Across five years, Non-cash Items topped out at $29.5 million in Q2 2022 and bottomed at -$91.2 million in Q3 2025.
- The 5-year median for Non-cash Items is -$149000.0 (2023), against an average of -$8.9 million.
- Biggest YoY gain for Non-cash Items was 75628.21% in 2022; the steepest drop was 73065.85% in 2022.
- Year by year, Non-cash Items stood at $29.5 million in 2022, then tumbled by 100.51% to -$149000.0 in 2023, then jumped by 15587.92% to $23.1 million in 2024, then plunged by 495.31% to -$91.2 million in 2025, then surged by 70.98% to -$26.5 million in 2026.
- Per Business Quant, the three latest CLLS Non-cash Items figures stand at -$26.5 million (Q1 2026), -$91.2 million (Q3 2025), and -$3.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.48 Mn |
| Mar 31, 2026 | -26.48 Mn |
| Sep 30, 2025 | -91.23 Mn |
| Sep 30, 2025 | -91.23 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Mar 31, 2025 | 927,000.00 |
| Mar 31, 2025 | 927,000.00 |
| Sep 30, 2024 | 23.08 Mn |
| Sep 30, 2024 | 23.08 Mn |
| Jun 30, 2024 | 13.47 Mn |
| Jun 30, 2024 | 13.47 Mn |
| Mar 31, 2024 | -13.47 Mn |
| Mar 31, 2024 | -13.47 Mn |
| Jun 30, 2023 | -149,000.00 |
| Jun 30, 2023 | -149,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Jun 30, 2022 | 29.46 Mn |
| Jun 30, 2022 | 29.46 Mn |